Liquid biopsies based on solid science
We offer cost-effective and comprehensive solutions for blood-based cancer genome profiling and residual disease detection. Our assays detect somatic mutations, copy number alterations, and chromosomal rearrangements from circulating tumor DNA fragments in blood. The service portfolio also includes customized assays and tumor tissue profiling.
Our research assays are tailored for individual cancer types, detecting somatic and germline DNA mutations, copy number alterations, and rearrangements in all genes of interest, along with a genome-wide copy number profile. With prices as low as 700€ per cell-free DNA or tissue sample, our assays are a great choice for genomic characterization, biomarker discovery, and resistance mechanism studies.Lung cancer Colorectal cancer Prostate cancer Breast cancer Bladder cancer Pancreatic cancer Ovarian cancer Liver cancer Skin cancer Whole exome Whole genome
Every person's blood carries billions of DNA fragments released from cells in their body. In a person with cancer, some of these fragments originate from cancer cells. Starting with only 8 mL of patient blood, we extract circulating DNA fragments and analyze them to characterize the cancer cells present in a patient's body. Please see our list of publications for more information.View example patient report
The Fluivia team has years of experience utilizing liquid biopsy analysis in clinical cancer research. We wish to partner with pharmaceutical companies, healthcare providers, and academic groups to advance clinical research and provide the best possible treatment for patients. Please contact us at firstname.lastname@example.org or through the contact form below to discuss how you could benefit from partnership with Fluivia.